On July 23, 2025, Rocket Pharmaceuticals announced a corporate restructuring plan to cut workforce by 30%, aiming to reduce operating expenses by nearly 25% and extend operational runway until mid-2027, incurring estimated charges of $3.5 million for severance and related costs.